Figure 2
Figure 2. Sample relationships are influenced by clinical and gene-expression characteristics. Two hundred sixty-four myeloma patient samples and 6 normal plasma cell control samples were subject to unsupervised hierarchical clustering based on 9174 differentially expressed probe sets. Highly related branches (labeled groups 1-5) were identified by setting a fixed similarity metric (GeneMaths software; Applied Maths, Austin, TX) and requiring at least 12 samples for membership; unlabeled samples comprise various smaller groups. (A) Patient attributes are encoded below the sample dendrogram. Attributes with nonrandom distribution (P < .05) are indicated by asterisks. Black is associated with age older than 60 years, female sex, IgG isotype, 1 or 2 prior therapies, hybridization batch 1 (trials 024, 025, and 040), and low purity score. White is associated with age 60 years and younger, male sex, other isotypes, 3 or more prior therapies, hybridization batch 2 (trial 039), and high purity score. (B) An overview of the 9174 differentially expressed probe sets, with an expansion of specific functional groups.

Sample relationships are influenced by clinical and gene-expression characteristics. Two hundred sixty-four myeloma patient samples and 6 normal plasma cell control samples were subject to unsupervised hierarchical clustering based on 9174 differentially expressed probe sets. Highly related branches (labeled groups 1-5) were identified by setting a fixed similarity metric (GeneMaths software; Applied Maths, Austin, TX) and requiring at least 12 samples for membership; unlabeled samples comprise various smaller groups. (A) Patient attributes are encoded below the sample dendrogram. Attributes with nonrandom distribution (P < .05) are indicated by asterisks. Black is associated with age older than 60 years, female sex, IgG isotype, 1 or 2 prior therapies, hybridization batch 1 (trials 024, 025, and 040), and low purity score. White is associated with age 60 years and younger, male sex, other isotypes, 3 or more prior therapies, hybridization batch 2 (trial 039), and high purity score. (B) An overview of the 9174 differentially expressed probe sets, with an expansion of specific functional groups.

Close Modal

or Create an Account

Close Modal
Close Modal